GLP-1
Semaglutide · Liraglutide
GLP-1 receptor agonists can increase feelings of fullness, reduce appetite and affect glucose-dependent insulin release and stomach emptying.
Explore semaglutide →How they work
A plain-English map of GLP-1, GIP, glucagon and MC4 receptor medicines — without turning mechanism into a self-prescribing guide.
Quick answer
Many common injections imitate or influence hormone signals involved in appetite, fullness, digestion and blood-glucose regulation. Others target different pathways or rare genetic conditions. The mechanism does not tell you whether a product is authorised, appropriate or available.
GLP-1
GLP-1 receptor agonists can increase feelings of fullness, reduce appetite and affect glucose-dependent insulin release and stomach emptying.
Explore semaglutide →GIP + GLP-1
Tirzepatide acts on two incretin receptor pathways. Its combined mechanism does not remove the need for individual assessment and monitoring.
Explore tirzepatide →MC4 receptor
This specialist medicine acts on a hunger-signalling pathway for defined genetic or acquired conditions; it is not a general GLP-1 alternative.
Explore setmelanotide →Research pathways
Retatrutide, survodutide and other trial medicines study additional receptor combinations. Research status is not permission to buy or inject them.
See the research pipeline →What mechanism cannot answer
Common questions
Different medicines work through different biological pathways. Common GLP-1 medicines can affect appetite, fullness, stomach emptying and glucose regulation; tirzepatide also acts on GIP receptors. Setmelanotide targets MC4 receptors for specific rare obesity conditions.
They are not simple fat-dissolving shots. Authorised medicines influence appetite or metabolic signalling as part of a broader treatment plan; changes in energy intake and health behaviours remain relevant.
There is no universal best option. Suitability depends on authorised indication, health history, other medicines, pregnancy plans, tolerability, access, follow-up and personal treatment goals.
Obesity is a chronic disease and response over time varies. Stopping, continuing or changing treatment is a clinical decision; a plan should include maintenance and follow-up rather than only a starting prescription.
Primary sources